Download PDF
J Knee Surg 2019; 32(03): 251-258
DOI: 10.1055/s-0038-1641141
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

A Meta-Analysis Comparing Liposomal Bupivacaine and Traditional Periarticular Injection for Pain Control after Total Knee Arthroplasty

Hao Sun
1   Department of Joint Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
,
Zhiyu Huang
1   Department of Joint Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
,
Zhiqi Zhang
1   Department of Joint Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
,
Weiming Liao
1   Department of Joint Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
› Author Affiliations
Further Information

Publication History

13 July 2017

25 February 2018

Publication Date:
04 April 2018 (online)

    Permissions and Reprints

Abstract

Liposomal bupivacaine is a novel method for pain control after total knee arthroplasty (TKA), but recent studies showed no advantage for patients undergoing TKA compared with traditional periarticular injection (PAI). The purpose of this analysis was to compare the clinical outcomes between liposomal bupivacaine treatment and traditional PAI. We retrospectively reviewed data from 16 clinical trials in published databases from their inception to June 2017. The primary outcome was postoperative Visual Analogue Scale (VAS) score and secondary outcomes included opiate usage, narcotic consumption, range of motion, and length of stay. Nine randomized controlled trials and seven nonrandomized controlled trials involving 924 liposomal bupivacaine cases and 1,293 traditional PAI cases were eligible for inclusion in the meta-analysis. No differences were detected in most of the clinical outcomes, except for postoperative VAS within 12 hours and length of stay. This analysis showed that liposomal bupivacaine is not associated with significant improvement in postoperative pain control or other outcomes in TKA compared with PAI.

Keywords

liposomal bupivacaine - periarticular injection - total knee arthroplasty - meta-analysis
 

  • References

  • 1 Kurtz SM, Ong KL, Lau E. , et al. International survey of primary and revision total knee replacement. Int Orthop 2011; 35 (12) 1783-1789
    CrossrefPubMedGoogle Scholar
  • 2 Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet 2006; 367 (9522): 1618-1625
    CrossrefPubMedGoogle Scholar
  • 3 Kessler ER, Shah M, Gruschkus SK, Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy 2013; 33 (04) 383-391
    CrossrefPubMedGoogle Scholar
  • 4 Kelley TC, Adams MJ, Mulliken BD, Dalury DF. Efficacy of multimodal perioperative analgesia protocol with periarticular medication injection in total knee arthroplasty: a randomized, double-blinded study. J Arthroplasty 2013; 28 (08) 1274-1277
    CrossrefPubMedGoogle Scholar
  • 5 Lamplot JD, Wagner ER, Manning DW. Multimodal pain management in total knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty 2014; 29 (02) 329-334
    CrossrefPubMedGoogle Scholar
  • 6 Jiang J, Teng Y, Fan Z, Khan MS, Cui Z, Xia Y. The efficacy of periarticular multimodal drug injection for postoperative pain management in total knee or hip arthroplasty. J Arthroplasty 2013; 28 (10) 1882-1887
    CrossrefPubMedGoogle Scholar
  • 7 Bramlett K, Onel E, Viscusi ER, Jones K. A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. Knee 2012; 19 (05) 530-536
    CrossrefPubMedGoogle Scholar
  • 8 Bagsby DT, Ireland PH, Meneghini RM. Liposomal bupivacaine versus traditional periarticular injection for pain control after total knee arthroplasty. J Arthroplasty 2014; 29 (08) 1687-1690
    CrossrefPubMedGoogle Scholar
  • 9 Schroer WC, Diesfeld PG, LeMarr AR, Morton DJ, Reedy ME. Does extended-release liposomal bupivacaine better control pain than bupivacaine after total knee arthroplasty (TKA)? A prospective, randomized clinical trial. J Arthroplasty 2015; 30 (9, Suppl): 64-67
    CrossrefPubMedGoogle Scholar
  • 10 Kenes MT, Leonard MC, Bauer SR, Wyman MJ. Liposomal bupivacaine versus continuous infusion bupivacaine via an elastomeric pump for the treatment of postoperative pain. Am J Health Syst Pharm 2015; 72 (23) (Suppl. 03) S127-S132
    CrossrefPubMedGoogle Scholar
  • 11 White S, Vaughan C, Raiff D, Eward W, Bolognesi M. Impact of liposomal bupivacaine administration on postoperative pain in patients undergoing total knee replacement. Pharmacotherapy 2015; 35 (05) 477-481
    CrossrefPubMedGoogle Scholar
  • 12 Kirkness CS, Asche CV, Ren J, Kim M, Rainville EC. Cost-benefit evaluation of liposomal bupivacaine in the management of patients undergoing total knee arthroplasty. Am J Health Syst Pharm 2016; 73 (09) e247-e254
    CrossrefPubMedGoogle Scholar
  • 13 Meneghini RM, Bagsby D, Ireland PH. , et al. Liposomal bupivacaine injection technique in total knee arthroplasty. J Knee Surg 2017; 30 (01) 88-96
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Wang Y, Klein MS, Mathis S, Fahim G. Adductor canal block with bupivacaine liposome versus ropivacaine pain ball for pain control in total knee arthroplasty: a retrospective cohort study. Ann Pharmacother 2016; 50 (03) 194-202
    CrossrefPubMedGoogle Scholar
  • 15 Barrington JW, Emerson RH, Lovald ST, Lombardi AV, Berend KR. No difference in early analgesia between liposomal bupivacaine injection and intrathecal morphine after TKA. Clin Orthop Relat Res 2017; 475 (01) 94-105
    CrossrefPubMedGoogle Scholar
  • 16 Klug MJ, Rivey MP, Carter JT. Comparison of intraoperative periarticular injections versus liposomal bupivacaine as part of a multimodal approach to pain management in total knee arthroplasty. Hosp Pharm 2016; 51 (04) 305-311
    CrossrefPubMedGoogle Scholar
  • 17 Collis PN, Hunter AM, Vaughn MD, Carreon LY, Huang J, Malkani AL. Periarticular injection after total knee arthroplasty using liposomal bupivacaine vs a modified Ranawat suspension: a prospective, randomized study. J Arthroplasty 2016; 31 (03) 633-636
    CrossrefPubMedGoogle Scholar
  • 18 Jain RK, Porat MD, Klingenstein GG, Reid JJ, Post RE, Schoifet SD. Liposomal bupivacaine and periarticular injection are not superior to single-shot intra-articular injection for pain control in total knee arthroplasty. J Arthroplasty 2016; 31 (9, Suppl): 22-25
    CrossrefPubMedGoogle Scholar
  • 19 Snyder MA, Scheuerman CM, Gregg JL, Ruhnke CJ, Eten K. Improving total knee arthroplasty perioperative pain management using a periarticular injection with bupivacaine liposomal suspension. Arthroplast Today 2016; 2 (01) 37-42
    PubMedGoogle Scholar
  • 20 Schwarzkopf R, Drexler M, Ma MW. , et al. Is there a benefit for liposomal bupivacaine compared to a traditional periarticular injection in total knee arthroplasty patients with a history of chronic opioid use?. J Arthroplasty 2016; 31 (08) 1702-1705
    CrossrefPubMedGoogle Scholar
  • 21 Alijanipour P, Tan TL, Matthews CN. , et al. Periarticular injection of liposomal bupivacaine offers no benefit over standard bupivacaine in total knee arthroplasty: a prospective, randomized, controlled trial. J Arthroplasty 2017; 32 (02) 628-634
    CrossrefPubMedGoogle Scholar
  • 22 DeClaire JH, Aiello PM, Warritay OK, Freeman DC. Effectiveness of bupivacaine liposome injectable suspension for postoperative pain control in total knee arthroplasty: a prospective, randomized, double blind, controlled study. J Arthroplasty 2017; 32 (9S): S268-S271
    CrossrefPubMedGoogle Scholar
  • 23 Grant GJ, Barenholz Y, Bolotin EM. , et al. A novel liposomal bupivacaine formulation to produce ultralong-acting analgesia. Anesthesiology 2005; 49 (01) 45-46
    PubMedGoogle Scholar
  • 24 Chahar P, Cummings III KC. Liposomal bupivacaine: a review of a new bupivacaine formulation. J Pain Res 2012; 5 (05) 257-264
    Google Scholar
  • 25 Okoroha KR, Keller RA, Marshall NE. , et al. Liposomal bupivacaine versus femoral nerve block for pain control after anterior cruciate ligament reconstruction: a prospective randomized trial. Arthroscopy 2016; 32 (09) 1838-1845
    CrossrefPubMedGoogle Scholar
  • 26 Surdam JW, Licini DJ, Baynes NT, Arce BR. The use of exparel (liposomal bupivacaine) to manage postoperative pain in unilateral total knee arthroplasty patients. J Arthroplasty 2015; 30 (02) 325-329
    CrossrefPubMedGoogle Scholar
  • 27 Kessler ER, Pierce DP, Whalen K. , et al. Response to “bupivacaine liposomal versus bupivacaine: comparative review.” Hosp Pharm 2014; 49 (09) 793-795
    CrossrefPubMed
  • 28 Kuang MJ, Du Y, Ma JX, He W, Fu L, Ma XL. The efficacy of liposomal bupivacaine using periarticular injection in total knee arthroplasty: a systematic review and meta-analysis. J Arthroplasty 2017; 32 (04) 1395-1402
    CrossrefPubMedGoogle Scholar
  • 29 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-560
    CrossrefPubMedGoogle Scholar
  • 30 Mashimo T, Uchida I, Pak M. , et al. Prolongation of canine epidural anesthesia by liposome encapsulation of lidocaine. Anesth Analg 1992; 74 (06) 827-834
    PubMedGoogle Scholar
  • 31 Cherian JJ, Muzaffar A, Barrington JW. , et al. Liposomal bupivacaine in total knee arthroplasty for better postoperative analgesic outcome and economic benefits. J Knee Surg 2016; 29 (03) 180-187
    Article in Thieme ConnectPubMedGoogle Scholar